April 22, 2020
Vivacelle Biosciences said it will make its experimental sepsis treatment VBI-S available for compassionate use in COVID-19 patients.
VBI-S is being investigated for treatment of decreased blood circulation due to sepsis and septic shock. In early studies, the drug improved blood pressure and oxygenation in patients when other measures failed.
The Chicago-based drugmaker is currently evaluating the drug in a phase 2a trial for hypotension in septic shock patients.